A Phase 1, Open-Label, Single-Sequence, 2-Period Study to Evaluate the Effect of Rifampin (a CYP3A Inducer) on the Pharmacokinetics of IPI-145 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
Price : $35 *
At a glance
- Drugs Duvelisib (Primary) ; Rifampicin
- Indications Allergic asthma; Bacterial infections; Haematological malignancies; Non-Hodgkin's lymphoma; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Infinity Pharmaceuticals
- 26 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 25 Sep 2013 New trial record